Human Epstein–Barr virus IgG Lateral flow dipstick kit 4572

$487.00

Summary

Mikrogen diagnostik lateral flow device (dipstick) for research use (RUO)
Human Epstein–Barr virus IgG Lateral flow dipstick kit 4572
Suitable for IgG detection
Ready-to-use
20 tests

SKU: 4572 Category: kits Tags: Epstein-Barr Virus, IgG, Lateral Flow Dipsticks

Weight	1 lbs
Dimensions	9 × 5 × 2 in
target	Human Epstein–Barr virus IgG
species reactivity	Human Epstein–Barr virus
applications	Lateral flow (dipstick)
assay type	Indirect & qualitative
available sizes	20 test kits

Human Epstein–Barr virus IgG Lateral flow dipstick kit 4572

Assay type
Sandwich assay, lateral flow (dipstick)

Research area
Infectious Disease

Sample type
Serum, plasma, whole blood

Components

10X Wash Buffer	100 mL
TMB Substrate	40 mL
Milk Powder	5 g
Instructions for Use	1 Each
Evaluation Form	1 Each
Test Strips	2 kits of [2 Vials x 10 Each]
Anti-Human IgG Conjugate	500 µL
Positive Control	140 µL
Negative Control	140 µL

Storage
Store at 2-8°C.

Additional information

Mikrogen recomLine EBV tests are serological, qualitative in vitro line immunoassays based on recombinantly produced, highly specific and characteristic EBV antigens. They are designed as screening tests. The line assay technique allows the detection and identification of IgG and IgM antibodies against the different antigen classes in one approach and at one glance.

Advantages

No disturbing interference with anticellular antibodies.
Patented p18Microgene as additional IgG marker for past infections.
New antigens: Highest sensitivity by BZLF1 in IgG and ZEBRA in IgM detection, in the early phase of acute infections.
In more than 95% of cases, past EBV infections can be correctly identified with the recomLine EBV IgG strip alone.
Simple and meaningful avidity determination - patented.
Separate detection of IgG and IgM antibodies.
Simple and clear interpretation due to easy-to-read banding.
Partial and full automation, software-based evaluation (recomScan), and integration with laboratory information system possible.
Highest sensitivity and specificity through the use of recombinant antigens:

Bands

EBV Antigen Group	Abbreviation	Recombinant Antigen	Size of Recombinant Antigen
Nuclear antigen	EBNA-1	p72	45 kDa
Virus capsid/structural antigen	VCA	p23	23 kDa
Virus capsid/structural antigen	VCA	p18	18 kDa
"Immediate Early Antigen"	IEA	ZEBRA (Peptid)	1.6 kDa
"Immediate Early Antigen"	IEA	BZLF1	30 kDa
"Early Antigen"	EA	p54	54 kDa
"Early Antigen"	EA	p138	40 kDa

target relevance
Organism Epstein-Barr Virus
Protein names Epstein-Barr Virus
Structure and strains The Epstein Barr virus (EBV), formally called Human gammaherpesvirus 4, is one of the nine known human herpesvirus types in the herpes family, and is one of the most common viruses in humans. EBV is a double-stranded DNA virus. Epstein-Barr virus (EBV) is the first identified oncogenic virus, which establishes permanent infection in humans. EBV causes infectious mononucleosis and is also tightly linked to many malignant diseases. Various vaccine formulations underwent testing in different animals or in humans. However, none of them was able to prevent EBV infection and no vaccine has been approved to date. The virus causes infectious mononucleosis ("mono" or "glandular fever"). It is also associated with various non-malignant, premalignant, and malignant Epstein Barr virus-associated lymphoproliferative diseases such as Burkitt lymphoma, hemophagocytic lymphohistiocytosis, and Hodgkin's lymphoma; non-lymphoid malignancies such as gastric cancer and nasopharyngeal carcinoma; and conditions associated with human immunodeficiency virus such as hairy leukoplakia and central nervous system lymphomas. The virus is also associated with the childhood disorders of Alice in Wonderland syndrome and acute cerebellar ataxia and, by some evidence, higher risks of developing certain autoimmune diseases, especially dermatomyositis, systemic lupus erythematosus, rheumatoid arthritis, and Sjogren's syndrome. About 200,000 cancer cases globally per year are thought to be attributable to EBV. In 2022, a large study (population of 10 million over 20 years) suggested EBV as the leading cause of multiple sclerosis, with a recent EBV infection causing a 32-fold increase in the risk of developing multiple sclerosis.
Detection and diagnosis IgG antibodies directed against early antigen (EA) and/or IgM antibodies against virus capsid antigens (VCA) in combination with negative EBNA1 IgG activity serve as evidence of acute primary infections. High IgG antibody activities against EBNA1 exclude acute primary infections. IgG antibodies directed against VCA can usually be detected life-long and serve as confirmation of contact with the pathogen. In reactivations, high IgG antibody activities directed against VCA and EA can frequently be found.

Data

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.